InVivo Therapeutics Holdings Co (NVIVQ)
- Previous Close
0.3600 - Open
0.3700 - Bid --
- Ask --
- Day's Range
0.3700 - 0.3740 - 52 Week Range
0.1500 - 1.6400 - Volume
1,122 - Avg. Volume
3,707,111 - Market Cap (intraday)
1.149M - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
www.invivotherapeutics.comRelated News
Performance Overview: NVIVQ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVIVQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVIVQ
Valuation Measures
Market Cap
1.15M
Enterprise Value
-7.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.13
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.79
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.71%
Return on Equity (ttm)
-98.11%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.33M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
8.58M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.03M